Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001104659-21-099691)

Filing Details

Accession Number:
0001104659-21-099691
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-03 21:45:25
Reporting Period:
2021-08-01
Accepted Time:
2021-08-03 21:45:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1657312 Verona Pharma Plc VRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1408502 W Mark Hahn 3 More London Riverside
London X0 SE1 2RE		 Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-08-01 454,840 $0.79 16,466,800 No 4 F Direct
Ordinary Shares Disposition 2021-08-02 10,416 $0.77 16,456,384 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
Footnotes
  1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
  2. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
  3. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 30, 2021 divided by eight (8).
  4. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
  5. The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7513 to $0.7838. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5.
  6. Consists of (i) 11,612,088 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,451,511 ADSs); and (ii) 4,844,296 Ordinary Shares underlying 605,537 ADSs.